Adjuvance Technologies, Inc.
Technology
Adjuvance is commercializing our proprietary Triterpene Saponin Synthesis Technology (TriSST™) platform. TriSST is a breakthrough technology that allows Adjuvance to reliably synthesize the world’s leading adjuvant molecule QS-21 as well as a robust pipeline of novel QS-21 analogs within our TiterQuil™ family of molecules.
TriSST
For the first time, TriSST provides a commercially viable source of QS-21 that is capable of large scale synthesis of pure materials for human use as well as a robust pipeline of novel adjuvant molecules. Natural QS-21 is difficult to procure through purification procedures and lacks the purity and raw materials necessary for robust commercialization. Instead of isolating a cumbersome natural product of indefinite composition, TriSST allows us to start with a synthetic core and modify the molecular quadrants separately, prior to late stage convergent assembly.
In addition to delivering quality, efficiency, and efficacy to QS-21 production, TriSST provides adaptability through our rationally designed structural variants.
Effecting very simple modifications to one portion (or more) of the molecule provides an infinite number of possibilities for unique TiterQuil molecules. TriSST represents a viable solution to the dearth of acceptable vaccine adjuvants. TriSST is the most reliable method of producing the world’s leading adjuvant candidate (QS-21) and is capable of providing an entire portfolio of novel adjuvant molecules with improving stability, toxicity, efficacy and cost profiles. TriSST is an innovative technology whose superiority provides the power, dependability and adaptability necessary to empower current-generation and next-generation vaccine formulations through our Saponex and TiterQuil molecules.